BNC-101 / Neuphoria Therapeutics, Carina Biotech - LARVOL DELTA

Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program (GlobeNewswire) - "On October 30, 2024, Carina Biotech...made a milestone payment of AUS$1M to Bionomics. The milestone payment was made under the terms of the exclusive, worldwide license agreement for BNC101, a monoclonal antibody targeting the cancer stem cell antigen LGR5, between the Company and Carina Biotech signed on November 2020....Based on the agreement, Bionomics is eligible to receive up to approximately AUS$118 million in certain development, regulatory and commercial milestone payments if Carina Biotech fully develops and markets the new therapy."

Financing • Solid Tumor

"$ETON Submits NDA for Topiramate Oral Solution (ET-101)" (,@BioStocks)

NDA